If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
The glymphatic clearance system is a brain-wide pathway for removal of waste solutes,
which depends upon the presence of aquaporin-4 (AQP4) channels, on the endfeet of
paravascular astrocytes in the brain (Iliff, et al. (2012)). Glymphatic function has
been shown to be impaired in mouse models of Alzheimer’s disease (AD) (Harrison et
al., (2016), Peng et al., (2016)), and both amyloid-β (Iliff et al., 2012) and tau
(Iliff et al., 2014) have been shown to be cleared from the brain via this system.
Until now however, it is unknown whether the glymphatic pathway presents as a suitable
drug target. Here we demonstrate that a novel AQP4 inhibitor,TGN-020, suppresses glymphatic
function and clearance of tau from the brain, suggesting that pharmacological manipulation
of AQP4 function may present as a novel drug target for the treatment of AD.
To read this article in full you will need to make a payment
One-time access price info
For academic or personal research use, select 'Academic and Personal'
For corporate R&D use, select 'Corporate R&D Professionals'